MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
The University of Texas MD Anderson Cancer Center and Exscientia plc announced a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
The research collaboration will utilize Exscientia’s precision medicine platform to identify novel anti-cancer, cell-intrinsic small-molecule compounds based on jointly identified therapeutic targets. Promising candidates will advance for further development with the team at MD Anderson’s Therapeutics Discovery division. The collaborators anticipate that successful target discovery programs may be advanced into proof-of-concept clinical trials at MD Anderson.
Exscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics. IACS is a core component of MD Anderson’s Therapeutics Discovery division, an integrated team of researchers, physicians and drug development experts working to advance impactful new therapies.
Under the agreement terms, Exscientia and MD Anderson will jointly contribute to and support each program designated to move forward.
